Novel Materials for Cancer Diagnostics and Treatment

A special issue of Journal of Functional Biomaterials (ISSN 2079-4983). This special issue belongs to the section "Biomaterials for Cancer Therapies".

Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 1907

Special Issue Editors


E-Mail Website
Guest Editor
Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China
Interests: control, design and synthesis of nanomaterials; nanomedicine; nanotoxicology

E-Mail Website
Guest Editor
Biomedical Sciences Group, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, B3000 Leuven, Belgium
Interests: cancer nanomedicine; infant respiratory diseases—mainly bronchopulmonary dysplasia; drug delivery systems; preclinical imaging (stronger focus on optical imaging); in vitro toxicology

Special Issue Information

Dear Colleagues,

Cancer is one of the deadliest diseases in the world today, posing a great threat to human life and health. Traditional treatments such as surgery, chemotherapy, and radiotherapy are key strategies for treating solid tumors, but these methods have limitations, including unavoidable side effects and difficulty in eradicating tumors. Clinical medicine urgently needs to develop novel treatment models to improve the efficiency of cancer treatment and relieve patients' suffering.

Fortunately, the properties of engineered nanomaterials can be precisely tuned by controlling their size, shape, synthesis conditions, and functionalization. Recently, engineered nanomaterial-based nanotheranostics have received widespread attention in the field of nanomedicine in applications such as drug delivery, sonodynamic therapy (SDT), photothermal therapy (PTT), and photodynamic therapy (PDT). However, there are still challenges such as unclear mechanism of action, low targeting efficiency, and poor biocompatibility. Therefore, the development of new low-toxicity nanotargeted drugs has become an urgent need.

This Special Issue (‘Novel Materials for Cancer Diagnostics and Treatment’) seeks to publish creative works that help to improve this situation. These studies should focus on the scope of the rational design of nanomaterials, bioimaging, targeted delivery drug systems, and non-invasive or minimally invasive treatment methods for cancer.

We look forward to receiving your submissions and working with you.

Dr. Shunhao Wang
Dr. Bella Manshian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel nanomaterials for biomedical applications
  • nanocarriers
  • precision cancer imaging
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 14121 KiB  
Article
Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY)
by Michele Moreau, Debarghya China, Gnagna Sy, Kai Ding and Wilfred Ngwa
J. Funct. Biomater. 2024, 15(10), 285; https://doi.org/10.3390/jfb15100285 - 27 Sep 2024
Viewed by 1378
Abstract
Smart radiotherapy biomaterials (SRBs) include seed and liquid biomaterials designed to be employed as fiducial markers during radiotherapy while also delivering therapeutic drug payloads to enhance treatment outcomes. In this study, we investigate a novel Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY [...] Read more.
Smart radiotherapy biomaterials (SRBs) include seed and liquid biomaterials designed to be employed as fiducial markers during radiotherapy while also delivering therapeutic drug payloads to enhance treatment outcomes. In this study, we investigate a novel Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY) biomaterial, which can be loaded with immunoadjuvants (anti-CD40 monoclonal antibody or Caflanone (FBL-03G)) at the point of care. The CLARITY biomaterial was investigated in an animal model of pancreatic cancer using C57BL6 mice. Mice were imaged before and at different points of time post-treatment to evaluate the potential of CLARITY biomaterial to provide imaging contrast similar to fiducials. This study also used cadavers to assess CLARITY’s potential to provide imaging contrast in humans. Results showed imaging contrast from computed tomography (CT) and magnetic resonance imaging (MRI) modalities for up to 30 days post-treatment, demonstrating potential for use as fiducials. A significant increase in survival (***, p = 0.0006) was observed for mice treated with CLARITY biomaterial loaded with immunoadjuvant for up to 10 weeks post-treatment compared to those without treatment. These initial results demonstrate the potential of CLARITY biomaterial to serve as a smart multifunctional radiotherapy biomaterial and provide the impetus for further development and optimization as a point-of-care technology for combination radiotherapy and immunotherapy. Full article
(This article belongs to the Special Issue Novel Materials for Cancer Diagnostics and Treatment)
Show Figures

Figure 1

Back to TopTop